Skip to main content
SpringerLink
Log in

Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis

  • Chapter
  • First Online:
Myeloproliferative Neoplasms

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 1010 Accesses

Abstract

Hematopoietic stem cell transplantation offers a curative therapy for patients with myelofibrosis. Due to toxicity, allografting following myeloablative regimens is mainly applicable to young patients. With the introduction of dose-reduced conditioning using busulfan or melphalan with fludarabine, transplantation became tolerable also in older patients. Improvement in management of transplant-related complications as well as increasing numbers of volunteer stem cell donors lead to an increased use of alternative donors. Through the discovery of new disease-specific mutations, close monitoring of residual disease became feasible in many patients, and the outcome of posttransplant strategies improved. Still challenging is achieving of new transplant-derived models to estimate risk status and possible outcome in every individual patient and help in therapy decision and determine optimal timing of stem cell transplantation. Such a tool may optimally include not only clinicomorphological characteristics but also other potentially relevant factors such as cytogenetics and novel molecular markers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alchalby H, Badbaran A, Bock O et al (2010a) Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic stem cell transplantation. Bone Marrow Transplant 45:1404–1407

    Article  PubMed  CAS  Google Scholar 

  • Alchalby H, Badbaran A, Zabelina T et al (2010b) Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 116:3572–3581

    Article  PubMed  CAS  Google Scholar 

  • Bacigalupo A, Dominetto A, Pozzi S et al (2007) Allogeneic hematopoietic stem transplant for patients with idiopathic myelofibrosis using a reduced intensity thiotepa based conditioning regimen. Blood 110: Abstract no. 684

    Google Scholar 

  • Bacigalupo A, Soraru M, Dominietto A et al (2010) Allogeneic hematopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 45:458–463

    Article  PubMed  CAS  Google Scholar 

  • Ballen K, Zhang M, Arora M, the Chronic Leukemia Working Committee of the Center for International Blood Marrow Transplant Research (2005) Outcome of bone marrow transplantation for myelofibrosis. Blood 106: Abstract no. 170

    Google Scholar 

  • Ballen KK, Shrestha S, Sobocinski KA et al (2010) Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 16(3):358–367. Epub 2009 Oct 30

    Google Scholar 

  • Baurmann H, Burlakova I, Jedlickova Z et al (2009) Allogeneic haematopoietic cell transplantation for myelofibrosis – close post-transplant surveillance is mandatory [abstract no. V59]. Presented the Corporate Annual Conference ’09 of the German, Austrian and Swiss Haematology and Oncology Societies. Mannheim/Heidelberg, Germany; 2–6 Oct 2009

    Google Scholar 

  • Benjamini O, Koren-Michowitz M, Amariglio N et al (2008) Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation. Leukemia 22:1961–1963

    Article  PubMed  CAS  Google Scholar 

  • Byrne JL, Beshti H, Clark D et al (2000) Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a ‘graft vs. myelofibrosis’ effect. Br J Haematol 108:430–433

    Article  PubMed  CAS  Google Scholar 

  • Cervantes F, Barosi G, Demory JL et al (1998) Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 102:684–690

    Article  PubMed  CAS  Google Scholar 

  • Cervantes F, Rovira M, Urbano-Ispizua A (2000) Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant 26:697–699

    Article  PubMed  CAS  Google Scholar 

  • Cervantes F, Passamonti F, Barosi G (2008) Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 22:905–914

    Article  PubMed  CAS  Google Scholar 

  • Cervantes F, Dupriez B, Pereira A et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895–2901

    Article  PubMed  CAS  Google Scholar 

  • Ciurea SO, Sadegi B, Wilbur A et al (2008) Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br J Haematol 141:80–83

    Article  PubMed  Google Scholar 

  • Creemers GJ, Lowenberg B, Hagenbeek A (1992) Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 82:772–773

    Article  PubMed  CAS  Google Scholar 

  • Deeg HJ, Gooley TA, Flowers ME et al (2003) Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 102:3912–3918

    Article  PubMed  CAS  Google Scholar 

  • Devine SM, Hoffman R, Verma A et al (2002) Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 99:2255–2258

    Article  PubMed  CAS  Google Scholar 

  • Dokal I, Jones L, Deenmamode M et al (1989) Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 71:158–160

    Article  PubMed  CAS  Google Scholar 

  • Dupriez B, Morel P, Demory JL et al (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88:1013–1018

    PubMed  CAS  Google Scholar 

  • Elliott MA, Verstovsek S, Dingli D et al (2007) Mono­cytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res 31:1503–1509

    Article  PubMed  CAS  Google Scholar 

  • George B, Kerridge I, Gottlieb D et al (2008) A reduced intensity conditioning protocol associated with excellent survival in patients with myelofibrosis. Bone Marrow Transplant 42:567–568

    Article  PubMed  CAS  Google Scholar 

  • Guardiola P, Anderson JE, Bandini GW et al (1999) Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 93:2831–2838

    PubMed  CAS  Google Scholar 

  • Gupta V, Kröger N, Aschan J et al (2009) A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. Bone Marrow Transplant 44:317–320

    Article  PubMed  CAS  Google Scholar 

  • Hertenstein B, Guardiola P, Finke J et al (2002) Non-myeloablative (NMA) stem cell transplantation (SCT) for myeloid metaplasia with myelofibrosis (MMM): a survey from the Chronic Leukemia Working Party of the EBMT. Blood 100:Abstract no. 70

    Google Scholar 

  • Hessling J, Kroger N, Werner M et al (2002) Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 119:769–772

    Article  PubMed  Google Scholar 

  • Hussein K, Huang J, Lasho T et al (2009) Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur J Haematol 82:255–259

    Article  PubMed  Google Scholar 

  • James C, Ugo V, Le Couedic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144–1148

    Article  PubMed  CAS  Google Scholar 

  • Kerbauy DM, Gooley TA et al (2007) Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 13:355–365

    Article  PubMed  Google Scholar 

  • Klyuchnikov E, Holler E, Bornhäuser M et al (2011) Donor lymphocyte infusions and/or second allogeneic stem cell transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allo­grafting. (manuscript submitted)

    Google Scholar 

  • Kröger N, Mesa RA (2008) Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia 22:474–486

    Article  PubMed  Google Scholar 

  • Kröger N, Zabelina T, Schieder H et al (2005) Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 128:690–697

    Article  PubMed  Google Scholar 

  • Kröger N, Badbaran A, Holler E et al (2007a) Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 109:1316–1321

    Article  PubMed  Google Scholar 

  • Kröger N, Holler E, Kobbe G et al (2007b) Dose-reduced conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. Results from a Multicenter Prospective Trial of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 110:Abstract no. 683

    Google Scholar 

  • Kröger N, Thiele J, Zander A et al (2007c) Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol 35:1719–1722

    Article  PubMed  Google Scholar 

  • Kröger N, Alchalby H, Klyuchnikov E et al (2009a) JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood 113:1866–1868

    Article  PubMed  Google Scholar 

  • Kröger N, Holler E, Kobbe G et al (2009b) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 114:5264–5270

    Article  PubMed  Google Scholar 

  • Li Z, Deeg HJ (2001) Pros and cons of splenectomy in patients with myelofibrosis undergoing stem cell transplantation. Leukemia 15:465–467

    Article  PubMed  CAS  Google Scholar 

  • Li Z, Gooley T, Applebaum FR (2001) Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. Blood 97:2180–2181

    Article  PubMed  CAS  Google Scholar 

  • Lissandre A, Bay J-O, Cahn J-Y et al (2011) Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis. Bone Marrow Transplant 46:557–561

    Article  PubMed  CAS  Google Scholar 

  • Merup M, Lazarevic V, Nahi H, Andreasson B, Malm C, Nilsson L et al (2006) Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol 135:367–373

    Article  PubMed  CAS  Google Scholar 

  • Mesa RA, Verstovsek S, Cervantes F et al (2007) Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 31:737–740

    Article  PubMed  Google Scholar 

  • Patriarca F, Bacigalupo A, Sperotto A et al (2008) Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 93:1514–1522

    Article  PubMed  CAS  Google Scholar 

  • Percy MJ, McMullin MF (2005) The V617F JAK2 mutation and the myeloproliferative disorders. Hematol Oncol 23:91–93

    Article  PubMed  CAS  Google Scholar 

  • Rajantie J, Sale GE, Deeg HJ et al (1986) Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation. Blood 67:1693–1697

    PubMed  CAS  Google Scholar 

  • Robin M, Tabrizi R, Mohty M et al (2010) Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Br J Haematol 152:331–339

    Article  PubMed  Google Scholar 

  • Rondelli D, Barosi G, Bacigalupo A et al (2005) Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 105:4115–4119

    Article  PubMed  CAS  Google Scholar 

  • Rumi E, Passamonti F, Arcaini L et al (2010) Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. Bone Marrow Transplant 45:798–800

    Article  PubMed  CAS  Google Scholar 

  • Sale GE, Deeg HJ, Porter BA (2006) Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading. Biol Blood Marrow Transplant 12:1285–1294

    Article  PubMed  Google Scholar 

  • Samuelson S, Sandmaier BM, Heslop HE et al (2011) Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60–78 years of age. Br J Haematol 153:76–82

    Article  PubMed  Google Scholar 

  • Smith RE, Chelmowski MK, Szabo EJ (1990) Myelofibrosis: a review of clinical and pathologic features and treatment. Crit Rev Oncol Hematol 10:305–314

    Article  PubMed  CAS  Google Scholar 

  • Soll E, Massumoto C, Clift RA et al (1995) Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood 86:4667–4673

    PubMed  CAS  Google Scholar 

  • Steckel NK, Koldehoff M, Ditschkowski M (2007) Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation. Transplantation 83:1518–1520

    Article  PubMed  CAS  Google Scholar 

  • Stewart WA, Pearce R, Kirkland KE et al on behalf of the British Society for Blood and Marrow Transplantation (2010) The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplant 45:1587–1593

    Google Scholar 

  • Tam CS, Abruzzo LV, Lin KI et al (2009) The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood 113:4171–4178

    Article  PubMed  CAS  Google Scholar 

  • Tefferi A (2005) Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 23:8520–8530

    Article  PubMed  CAS  Google Scholar 

  • Tefferi A, Mesa RA, Nagorney DM (2000) Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 95:2226–2233

    PubMed  CAS  Google Scholar 

  • Tefferi A, Barosi G, Mesa RA et al (2006) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for MYelofibrosis Research and Treatment (IWG-MRT). Blood 108:1497–1503

    Article  PubMed  CAS  Google Scholar 

  • Thiele J, Kvasnicka HM, Dietrich H et al (2005) Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. Histol Histopathol 20:879–889

    PubMed  CAS  Google Scholar 

  • Vannucchi AM, Antonioli E, Guglielmelli P (2008) Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 22:1299–1307

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany

    Nicolaus Kröger

Authors
  1. Nicolaus Kröger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicolaus Kröger .

Editor information

Editors and Affiliations

  1. Div. Ematologia, Ospedali Riuniti di Bergamo, Largo Barozzi 1, Bergamo, 24128, Italy

    Tiziano Barbui

  2. Dept. Internal Medicine, Div. Hematology, Mayo Clinic, First Street SW. 200, Rochester, 55905, Minnesota, USA

    Ayalew Tefferi

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kröger, N. (2012). Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis. In: Barbui, T., Tefferi, A. (eds) Myeloproliferative Neoplasms. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-24989-1_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-24989-1_16

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-24988-4

  • Online ISBN: 978-3-642-24989-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation